

## Freedom of Information (Scotland) Act 2002

<b>Date received</b>	31/08/2022	<b>Subject</b>	Breast Cancer treatment		
<b>Passed to</b>	Pharmacy Specialist Nurses	<b>Date passed</b>	31/08/2022	<b>Respond by</b>	15/09/2022
<b>Category</b>	Research	<b>FOI number</b>	2022-360		

### Question/s to be answered

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- Abemaciclib (Verzenios) + aromatase inhibitor \*
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
- Alpelisib (Piqray) + Fulvestrant (Faslodex)
- Atezolizumab (Tecentriq)\*\*
- Bevacizumab (Avastin)
- Eribulin (Halaven)
- Everolimus (Afinitor) + Exemestane
- Fulvestrant (Faslodex) as a single agent

= 1

## Freedom of Information (Scotland) Act 2002

- Gemcitabine + paclitaxel
  - Herceptin (Trastuzumab) + paclitaxel  
=1
  - Herceptin (Trastuzumab) as a single agent  
=1
  - Lapatinib (Tyverb)
  - Neratinib (Nerlynx)
  - Olaparib (Lynparza)
  - Palbociclib (Ibrance) + aromatase inhibitor\*  
=6
  - Palbociclib (Ibrance) + Fulvestrant (Faslodex)
  - Pertuzumab (Perjeta) + trastuzumab + docetaxel  
=1
  - Ribociclib (Kisqali) + aromatase inhibitor\*
  - Ribociclib (Kisqali) + Fulvestrant (Faslodex)
  - Talazoparib (Talzenna)

## Freedom of Information (Scotland) Act 2002

- Trastuzumab emtansine (Kadcyla)

=1

- Other active systemic anti-cancer therapy \*\*

\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent

Docetaxel

= 1

Capecitabine

= 3

EC 90

=2

2. For the above patients, how many of these received their first ever dose for each product line?

= 0